Goundappa K Balasubramani1, Mary Patricia Nowalk2, Theresa M Sax1, Joe Suyama3, Emily Bobyock1, Charles R Rinaldo4, Emily T Martin5, Arnold S Monto5, Michael L Jackson6, Manjusha J Gaglani7, Brendan Flannery8, Jessie R Chung8, Richard K Zimmerman2. 1. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 2. Department of Family Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Emergency Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 5. School of Public Health, University of Michigan, Ann Arbor, MI, USA. 6. Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA. 7. Baylor Scott & White Health, Texas A&M University College of Medicine, Temple, TX, USA. 8. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
BACKGROUND: Influenza vaccination is recommended for all US residents aged ≥6 months. Vaccine effectiveness (VE) varies by age, circulating influenza strains, and the presence of high-risk medical conditions. We examined site-specific VE in the US Influenza VE Network, which evaluates annual influenza VE at ambulatory clinics in geographically diverse sites. METHODS: Analyses were conducted on 27 180 outpatients ≥6 months old presenting with an acute respiratory infection (ARI) with cough of ≤7-day duration during the 2011-2016 influenza seasons. A test-negative design was used with vaccination status defined as receipt of ≥1 dose of any influenza vaccine according to medical records, registries, and/or self-report. Influenza infection was determined by reverse-transcription polymerase chain reaction. VE estimates were calculated using odds ratios from multivariable logistic regression models adjusted for age, sex, race/ethnicity, time from illness onset to enrollment, high-risk conditions, calendar time, and vaccination status-site interaction. RESULTS: For all sites combined, VE was statistically significant every season against all influenza and against the predominant circulating strains (VE = 19%-50%) Few differences among four sites in the US Flu VE Network were evident in five seasons. However, in 2015-16, overall VE in one site was 24% (95% CI = -4%-44%), while VE in two other sites was significantly higher (61%, 95% CI = 49%-71%; P = .002, and 53%, 95% CI = 33,67; P = .034). CONCLUSION: With few exceptions, site-specific VE estimates aligned with each other and overall VE estimates. Observed VE may reflect inherent differences in community characteristics of the sites and highlights the importance of diverse settings for studying influenza vaccine effectiveness.
BACKGROUND: Influenza vaccination is recommended for all US residents aged ≥6 months. Vaccine effectiveness (VE) varies by age, circulating influenza strains, and the presence of high-risk medical conditions. We examined site-specific VE in the US Influenza VE Network, which evaluates annual influenza VE at ambulatory clinics in geographically diverse sites. METHODS: Analyses were conducted on 27 180 outpatients ≥6 months old presenting with an acute respiratory infection (ARI) with cough of ≤7-day duration during the 2011-2016 influenza seasons. A test-negative design was used with vaccination status defined as receipt of ≥1 dose of any influenza vaccine according to medical records, registries, and/or self-report. Influenza infection was determined by reverse-transcription polymerase chain reaction. VE estimates were calculated using odds ratios from multivariable logistic regression models adjusted for age, sex, race/ethnicity, time from illness onset to enrollment, high-risk conditions, calendar time, and vaccination status-site interaction. RESULTS: For all sites combined, VE was statistically significant every season against all influenza and against the predominant circulating strains (VE = 19%-50%) Few differences among four sites in the US Flu VE Network were evident in five seasons. However, in 2015-16, overall VE in one site was 24% (95% CI = -4%-44%), while VE in two other sites was significantly higher (61%, 95% CI = 49%-71%; P = .002, and 53%, 95% CI = 33,67; P = .034). CONCLUSION: With few exceptions, site-specific VE estimates aligned with each other and overall VE estimates. Observed VE may reflect inherent differences in community characteristics of the sites and highlights the importance of diverse settings for studying influenza vaccine effectiveness.
Authors: Angela Gentile; John Paget; Nancy Bellei; Juan Pablo Torres; Cynthia Vazquez; V Alberto Laguna-Torres; Stanley Plotkin Journal: Vaccine Date: 2019-04-08 Impact factor: 3.641
Authors: Edward A Belongia; Melissa D Simpson; Jennifer P King; Maria E Sundaram; Nicholas S Kelley; Michael T Osterholm; Huong Q McLean Journal: Lancet Infect Dis Date: 2016-04-06 Impact factor: 25.071
Authors: Jay V DePasse; Mary Patricia Nowalk; Kenneth J Smith; Jonathan M Raviotta; Eunha Shim; Richard K Zimmerman; Shawn T Brown Journal: Vaccine Date: 2017-06-09 Impact factor: 3.641
Authors: Maryam Darvishian; Frederika Dijkstra; Eva van Doorn; Maarten J Bijlsma; Gé A Donker; Marit M A de Lange; Laura M Cadenau; Eelko Hak; Adam Meijer Journal: PLoS One Date: 2017-01-09 Impact factor: 3.240
Authors: Brendan Flannery; Richard K Zimmerman; Larisa V Gubareva; Rebecca J Garten; Jessie R Chung; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Suzanne E Ohmit; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Pedro A Piedra; Vasiliy P Mishin; Anton P Chesnokov; Sarah Spencer; Swathi N Thaker; John R Barnes; Angie Foust; Wendy Sessions; Xiyan Xu; Jacqueline Katz; Alicia M Fry Journal: J Infect Dis Date: 2016-05-06 Impact factor: 7.759
Authors: Goundappa K Balasubramani; Mary Patricia Nowalk; Theresa M Sax; Joe Suyama; Emily Bobyock; Charles R Rinaldo; Emily T Martin; Arnold S Monto; Michael L Jackson; Manjusha J Gaglani; Brendan Flannery; Jessie R Chung; Richard K Zimmerman Journal: Influenza Other Respir Viruses Date: 2020-04-16 Impact factor: 5.606